MBX Biosciences (MBX) Competitors $13.75 +0.50 (+3.77%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.72 -0.03 (-0.18%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MBX vs. OCUL, ARQT, SPRY, APGE, IMCR, TARS, SRPT, ADPT, SDGR, and EVOShould you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include Ocular Therapeutix (OCUL), Arcutis Biotherapeutics (ARQT), ARS Pharmaceuticals (SPRY), Apogee Therapeutics (APGE), Immunocore (IMCR), Tarsus Pharmaceuticals (TARS), Sarepta Therapeutics (SRPT), Adaptive Biotechnologies (ADPT), Schrodinger (SDGR), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. MBX Biosciences vs. Its Competitors Ocular Therapeutix Arcutis Biotherapeutics ARS Pharmaceuticals Apogee Therapeutics Immunocore Tarsus Pharmaceuticals Sarepta Therapeutics Adaptive Biotechnologies Schrodinger Evotec MBX Biosciences (NYSE:MBX) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk. Which has better valuation and earnings, MBX or OCUL? MBX Biosciences has higher earnings, but lower revenue than Ocular Therapeutix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/AN/AN/AOcular Therapeutix$63.72M29.80-$193.51M-$1.15-10.37 Do institutionals and insiders have more ownership in MBX or OCUL? 59.2% of Ocular Therapeutix shares are owned by institutional investors. 52.2% of MBX Biosciences shares are owned by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer MBX or OCUL? In the previous week, Ocular Therapeutix had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 3 mentions for Ocular Therapeutix and 1 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.16 beat Ocular Therapeutix's score of 0.46 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is MBX or OCUL more profitable? MBX Biosciences has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -323.09%. MBX Biosciences' return on equity of 0.00% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A Ocular Therapeutix -323.09%-59.92%-41.98% Do analysts rate MBX or OCUL? MBX Biosciences currently has a consensus price target of $37.57, indicating a potential upside of 173.25%. Ocular Therapeutix has a consensus price target of $17.33, indicating a potential upside of 45.41%. Given MBX Biosciences' higher probable upside, research analysts clearly believe MBX Biosciences is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Ocular Therapeutix 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryMBX Biosciences beats Ocular Therapeutix on 7 of the 10 factors compared between the two stocks. Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMBX BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$459.58M$763.52M$5.48B$20.68BDividend YieldN/A4.84%4.73%3.67%P/E RatioN/A1.3428.6729.07Price / SalesN/A25.20373.9066.27Price / CashN/A19.5635.4522.84Price / BookN/A6.778.274.43Net IncomeN/A-$4.28M$3.24B$994.22M7 Day Performance-5.63%-4.26%-3.69%-3.35%1 Month Performance11.52%0.54%4.33%-2.06%1 Year PerformanceN/A15.94%25.95%10.15% MBX Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMBX Biosciences2.6586 of 5 stars$13.75+3.8%$37.57+173.2%N/A$459.58MN/A0.0036Positive NewsGap DownOCULOcular Therapeutix3.6107 of 5 stars$12.02-0.5%$17.33+44.2%+47.7%$1.91B$63.72M-10.41230Upcoming EarningsARQTArcutis Biotherapeutics2.5048 of 5 stars$15.05+0.6%$19.40+28.9%+50.7%$1.79B$212.82M-14.44150News CoveragePositive NewsUpcoming EarningsSPRYARS Pharmaceuticals3.204 of 5 stars$17.99-2.0%$31.00+72.3%+63.8%$1.76B$89.15M-112.3090Positive NewsUpcoming EarningsAPGEApogee Therapeutics2.4749 of 5 stars$38.34-3.3%$99.00+158.2%-17.5%$1.76BN/A-10.6191Positive NewsIMCRImmunocore1.7414 of 5 stars$34.86+2.7%$58.89+68.9%-16.7%$1.75B$333.58M-81.16320News CoverageUpcoming EarningsTARSTarsus Pharmaceuticals2.5317 of 5 stars$40.27-3.5%$66.67+65.5%+74.2%$1.69B$233.67M-14.7650Positive NewsUpcoming EarningsSRPTSarepta Therapeutics4.71 of 5 stars$16.36+18.0%$49.12+200.3%-89.0%$1.64B$1.90B-6.191,372Trending NewsUpcoming EarningsAnalyst ForecastOptions VolumeHigh Trading VolumeADPTAdaptive Biotechnologies3.0058 of 5 stars$10.39-2.1%$10.57+1.7%+132.1%$1.58B$178.96M-10.83790Positive NewsUpcoming EarningsGap DownSDGRSchrodinger2.5882 of 5 stars$21.34-4.7%$32.75+53.5%-13.6%$1.57B$207.54M-8.11790Positive NewsUpcoming EarningsGap DownEVOEvotec2.0865 of 5 stars$4.23-0.7%$5.90+39.5%-13.2%$1.50B$788.22M0.004,827News Coverage Related Companies and Tools Related Companies Ocular Therapeutix Competitors Arcutis Biotherapeutics Competitors ARS Pharmaceuticals Competitors Apogee Therapeutics Competitors Immunocore Competitors Tarsus Pharmaceuticals Competitors Sarepta Therapeutics Competitors Adaptive Biotechnologies Competitors Schrodinger Competitors Evotec Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MBX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.